Business
You are Watching: Making Money in Biotech, the JMP Securities Way - Part III: A few Stock Picks Allos, Cytokinetics, Orexigen, and Sangamo or just a few of JMP Securities stock picks for the end of the year. Charles Duncan explains how they are at a pivotal moment in their growth, and therefore best positioned to generate large returns for investors. Charles gives us some details about the company, the ongoing clinical trials, and the type of news we should expect in the months to come. This interview was conducted at the NASDAQ Marketsite, on September 9th, 2008, in New York City. Featuring: * Charles Duncan, Managing Director and Senior Biotechnology Analyst, JMP Securities * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV Disclaimer for JMP Securities: JMP makes a market in ALTH, CELG, CYTK, OREX and SGMO In addition, JMP Securities was a manager or co-manager of a public offering of OREX in the past 12 months DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.